But biomarker enrichment and toxicity remain key for FX-909.
ApexOnco Front Page
Recent articles
The month saw the first commissioner's priority voucher approval in oncology.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
